DP112 | UPDATED INTERIM RESULTS OF SONROTOCLAX + DEXAMETHASONE IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN ALL-ORAL TREATMENT

BACKGROUND: Sonrotoclax (sonro; BGB-11417), a next-generation BCL2 inhibitor, is a more selective and pharmacologically potent inhibitor of BCL2 than venetoclax. BGB-11417-105 (NCT04973605) is an ongoing phase 1b/2 study of sonro as mono- or combination therapy in patients (pts) with t(11;14)-posit...

全面介绍

书目详细资料

Principais autores:	C. Cerchione, B. Dhakal, M. Hultcrantz, N. Nathwani, C.P. Venner, J. Lu, M.J. Slade, J.L. Kaufman, H. Chuah, C-K. Min, K. Kim, H. Cheng, A. Idoine, W. Zhang, X. Wang, A. Agarwal, H. Quach
格式:	Artigo
语言:	Inglês
出版:	Ferrata Storti Foundation 2025-09-01
丛编:	Haematologica
在线阅读:	https://haematologica.org/article/view/12599
标签:	添加标签 没有标签, 成为第一个标记此记录!